SG11201406347TA - Humanized tau antibody - Google Patents
Humanized tau antibodyInfo
- Publication number
- SG11201406347TA SG11201406347TA SG11201406347TA SG11201406347TA SG11201406347TA SG 11201406347T A SG11201406347T A SG 11201406347TA SG 11201406347T A SG11201406347T A SG 11201406347TA SG 11201406347T A SG11201406347T A SG 11201406347TA SG 11201406347T A SG11201406347T A SG 11201406347TA
- Authority
- SG
- Singapore
- Prior art keywords
- tau antibody
- humanized tau
- humanized
- antibody
- tau
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261620880P | 2012-04-05 | 2012-04-05 | |
| PCT/US2013/032341 WO2013151762A1 (en) | 2012-04-05 | 2013-03-15 | Humanized tau antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201406347TA true SG11201406347TA (en) | 2014-11-27 |
Family
ID=48048231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201406347TA SG11201406347TA (en) | 2012-04-05 | 2013-03-15 | Humanized tau antibody |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9657091B2 (en) |
| EP (1) | EP2834270B1 (en) |
| JP (1) | JP6293731B2 (en) |
| KR (1) | KR102132041B1 (en) |
| CN (1) | CN104520322B (en) |
| AR (1) | AR092818A1 (en) |
| AU (1) | AU2013243861A1 (en) |
| BR (1) | BR112014024769A2 (en) |
| CA (1) | CA2869438C (en) |
| HK (1) | HK1209137A1 (en) |
| IL (1) | IL234942A0 (en) |
| MX (1) | MX356800B (en) |
| RU (1) | RU2644242C2 (en) |
| SG (1) | SG11201406347TA (en) |
| TW (1) | TW201400505A (en) |
| WO (1) | WO2013151762A1 (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9540434B2 (en) * | 2011-10-07 | 2017-01-10 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
| MX356800B (en) | 2012-04-05 | 2018-06-13 | Ac Immune Sa | Humanized tau antibody. |
| SG11201408626YA (en) | 2012-07-03 | 2015-03-30 | Univ Washington | Antibodies to tau |
| PT2885010T (en) | 2012-08-16 | 2020-03-11 | Ipierian Inc | Methods of treating a tauopathy |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
| CN105143258B (en) * | 2013-03-15 | 2020-06-23 | Ac免疫有限公司 | anti-Tau antibodies and methods of use |
| MX2016007208A (en) * | 2013-12-20 | 2016-07-21 | Hoffmann La Roche | HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE. |
| EP3104870A4 (en) | 2014-02-14 | 2017-09-13 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
| AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
| TWI664190B (en) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | Humanized anti-tau antibodies |
| CA2966964A1 (en) * | 2014-11-19 | 2016-05-26 | Michal Novak | Humanized tau antibodies in alzheimer's disease |
| EP4219530A1 (en) | 2014-12-05 | 2023-08-02 | City of Hope | Cs1 targeted chimeric antigen receptor-modified t cells |
| TWI669314B (en) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | Antibodies to tau and uses thereof |
| PE20180317A1 (en) | 2015-06-05 | 2018-02-09 | Genentech Inc | ANTI-TAU ANTIBODIES AND METHODS OF USE |
| EP3744732A1 (en) | 2015-06-24 | 2020-12-02 | F. Hoffmann-La Roche AG | Humanized anti-tau(ps422) antibodies and methods of use |
| CA2991264C (en) | 2015-07-06 | 2023-10-10 | Ucb Biopharma Sprl | Tau-binding antibodies |
| JO3711B1 (en) | 2015-07-13 | 2021-01-31 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| WO2017037158A1 (en) * | 2015-09-01 | 2017-03-09 | Oncoqr Ml Gmbh | Coiled-coil connector |
| WO2017191560A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| JP7170316B2 (en) | 2016-05-02 | 2022-11-14 | プロセナ バイオサイエンシーズ リミテッド | Tau immunotherapy |
| MY197413A (en) | 2016-05-02 | 2023-06-16 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| CN116041504A (en) | 2016-07-12 | 2023-05-02 | H.隆德贝克有限公司 | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| CN117820467A (en) | 2016-12-07 | 2024-04-05 | 基因泰克公司 | anti-TAU antibodies and methods of use |
| KR102587130B1 (en) | 2016-12-07 | 2023-10-11 | 제넨테크, 인크. | Anti-tau antibodies and methods of using the same |
| MA47499A (en) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc | ANTI-TAU BODIES AND THEIR METHODS OF USE |
| WO2018204546A2 (en) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
| US10829547B2 (en) | 2017-10-16 | 2020-11-10 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| CN111587123A (en) * | 2017-11-09 | 2020-08-25 | 品通治疗有限公司 | Methods and compositions for generating and using humanized conformation-specific phosphorylated tau antibodies |
| JP2021530552A (en) | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | Combination therapy |
| AU2018446059A1 (en) * | 2018-10-17 | 2021-05-20 | The University Of Queensland | Methods and compositions for treating tauopathies |
| BR112021016947A2 (en) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Antibodies that recognize tau |
| JP2022541539A (en) * | 2019-07-15 | 2022-09-26 | アデル，インコーポレーテッド | Anti-tau antibodies and uses thereof |
| CA3148740A1 (en) * | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN116693682B (en) * | 2023-06-02 | 2024-04-19 | 涌源合生科技(深圳)有限公司 | Anti-Tau protein antibody, preparation method and application thereof |
| CN116948025B (en) * | 2023-09-14 | 2024-04-02 | 北京凯祥弘康生物科技有限公司 | Antibody for resisting Tau protein |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| DE3883899T3 (en) | 1987-03-18 | 1999-04-22 | Sb2 Inc | CHANGED ANTIBODIES. |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5843708A (en) | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
| US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
| ATE191853T1 (en) | 1992-07-27 | 2000-05-15 | Us Health | TARGETING LIPOSOMES FOR THE BLOOD-BRAIN BARRIER |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69318420T2 (en) | 1992-12-14 | 1999-01-28 | Innogenetics Nv | MONOCLONAL ANTIBODIES AGAINST THE MICROTUBULUS ASSOCIATED TAUPROTEIN, HYBRIDOMES THAT SECRETORE THESE ANTIBODIES, ANTIGENT DETECTION THROUGH THESE MONOCLONAL ANTIBODIES AND THE USE THEREOF |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| PT804584E (en) | 1994-10-21 | 2002-11-29 | Innogenetics Nv | SEQUENCES OF VIRUSES OF HEPATITIS C GENOTYPE 7 AND ITS USE AS PROPRIETARY THERAPEUTIC AND DIAGNOSTIC AGENTS |
| US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| WO1997034145A1 (en) | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Antiphosphorylated tau protein antibody and method for detecting alzheimer's disease with the use of the same |
| AU5508798A (en) | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
| ATE375365T1 (en) | 1998-04-02 | 2007-10-15 | Genentech Inc | ANTIBODIES VARIANTS AND FRAGMENTS THEREOF |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| KR101077001B1 (en) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | Polypeptide Variants with Altered Effector Function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20050221391A1 (en) | 2000-07-11 | 2005-10-06 | Peter Davies | Reagents and methods for identification of binding agents |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| WO2002017930A2 (en) | 2000-08-30 | 2002-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| DE10121982B4 (en) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanoparticles of protein with coupled apolipoprotein E to overcome the blood-brain barrier and process for their preparation |
| EP2147679B1 (en) | 2001-07-25 | 2014-06-25 | Raptor Pharmaceutical, Inc. | Compositions for blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| KR101111477B1 (en) | 2002-12-03 | 2012-02-23 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | A conjugate comprising cholesterol linked to a therapeutic agent |
| SI2289936T1 (en) | 2002-12-16 | 2017-10-30 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| WO2004058239A1 (en) | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| JPWO2004105825A1 (en) | 2003-01-10 | 2006-07-20 | 多木化学株式会社 | Biomaterial for bone formation, formulation for injection containing the material, kit for preparing the material, and bone formation method using them |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| WO2004110472A2 (en) * | 2003-06-12 | 2004-12-23 | Eli Lilly And Company | Fusion proteins |
| US20050089473A1 (en) | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| US20050261475A1 (en) | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
| WO2005080986A1 (en) | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
| EP1959991B1 (en) | 2005-12-12 | 2013-03-20 | AC Immune S.A. | Therapeutic vaccine |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| WO2008140639A2 (en) | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
| EP2210901A4 (en) | 2007-10-19 | 2012-04-25 | Immunas Pharma Inc | Antibody capable of specifically binding to a oligomer, and use thereof |
| JP2012520852A (en) | 2009-03-18 | 2012-09-10 | エーシー イミューン ソシエテ アノニム | Methods for therapeutic use |
| UA107571C2 (en) | 2009-04-03 | 2015-01-26 | PHARMACEUTICAL COMPOSITION | |
| EP2440234A4 (en) | 2009-06-10 | 2013-11-06 | Univ New York | Immunological targeting of pathological tau proteins |
| KR20130127547A (en) | 2009-07-30 | 2013-11-22 | 화이자 백신스 엘엘씨 | Antigenic tau peptides and uses thereof |
| ES2548686T3 (en) * | 2010-10-07 | 2015-10-20 | Ac Immune S.A. | Antibodies that recognize phospho-Tau |
| US9540434B2 (en) | 2011-10-07 | 2017-01-10 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
| MX356800B (en) | 2012-04-05 | 2018-06-13 | Ac Immune Sa | Humanized tau antibody. |
-
2013
- 2013-03-15 MX MX2014011958A patent/MX356800B/en active IP Right Grant
- 2013-03-15 SG SG11201406347TA patent/SG11201406347TA/en unknown
- 2013-03-15 JP JP2015504600A patent/JP6293731B2/en active Active
- 2013-03-15 BR BR112014024769A patent/BR112014024769A2/en not_active Application Discontinuation
- 2013-03-15 CN CN201380029178.2A patent/CN104520322B/en active Active
- 2013-03-15 RU RU2014144331A patent/RU2644242C2/en active
- 2013-03-15 US US14/390,085 patent/US9657091B2/en active Active
- 2013-03-15 AU AU2013243861A patent/AU2013243861A1/en not_active Abandoned
- 2013-03-15 EP EP13714429.1A patent/EP2834270B1/en active Active
- 2013-03-15 KR KR1020147031163A patent/KR102132041B1/en active IP Right Grant
- 2013-03-15 CA CA2869438A patent/CA2869438C/en active Active
- 2013-03-15 WO PCT/US2013/032341 patent/WO2013151762A1/en active Application Filing
- 2013-04-03 TW TW102112202A patent/TW201400505A/en unknown
- 2013-04-05 AR ARP130101127A patent/AR092818A1/en unknown
-
2014
- 2014-10-02 IL IL234942A patent/IL234942A0/en unknown
-
2015
- 2015-10-06 HK HK15109752.2A patent/HK1209137A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013151762A1 (en) | 2013-10-10 |
| CA2869438C (en) | 2021-08-17 |
| JP2015521158A (en) | 2015-07-27 |
| HK1209137A1 (en) | 2016-03-24 |
| EP2834270A1 (en) | 2015-02-11 |
| IL234942A0 (en) | 2014-12-31 |
| US9657091B2 (en) | 2017-05-23 |
| AU2013243861A1 (en) | 2014-10-23 |
| RU2644242C2 (en) | 2018-02-08 |
| RU2014144331A (en) | 2016-05-27 |
| CN104520322A (en) | 2015-04-15 |
| AR092818A1 (en) | 2015-05-06 |
| KR102132041B1 (en) | 2020-07-09 |
| JP6293731B2 (en) | 2018-03-14 |
| MX2014011958A (en) | 2015-05-11 |
| TW201400505A (en) | 2014-01-01 |
| CA2869438A1 (en) | 2013-10-10 |
| KR20150003274A (en) | 2015-01-08 |
| MX356800B (en) | 2018-06-13 |
| BR112014024769A2 (en) | 2017-12-12 |
| US20150175682A1 (en) | 2015-06-25 |
| EP2834270B1 (en) | 2019-10-30 |
| CN104520322B (en) | 2019-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1209137A1 (en) | Humanized tau antibody tau | |
| IL264558A (en) | Anti-il-23p19 antibodies | |
| ZA201407509B (en) | Anti-fcrn antibodies | |
| HK1204571A1 (en) | Protease-regulated antibodies | |
| HK1210192A1 (en) | Anti-siglec-15 antibodies siglec-15 | |
| EP2922874A4 (en) | Bispecific antibody | |
| EP2930240A4 (en) | Anti-folr1 antibody | |
| ZA201407316B (en) | Anti-fgfr2 antibody | |
| EP2832855A4 (en) | Novel anti-siglec-15 antibody | |
| AP2014008002A0 (en) | Anti-baff-anti-IL-17 bispecific antibodies | |
| EP2826790A4 (en) | Gremlin-1 antibody | |
| ZA201407079B (en) | Cdr-modified anti-siglec-15 antibody | |
| HK1210186A1 (en) | Anti-h7cr antibodies h7cr | |
| PL2935330T3 (en) | Anti-notch3 antibodies | |
| GB201220242D0 (en) | Antibody | |
| EP2848633A4 (en) | Anti-cxadr antibody | |
| EP2811018A4 (en) | ANTI-sAPPß ANTIBODY | |
| IL235188A0 (en) | Anti-pdgf-c antibodies |